Increasing emergence of multidrug resistant (MDR) bacteria worldwide is now considered one of the most urgent threats to global health. The association between increase of antibiotics consumption and resistance emergence has been well documented for all patients admitted to the Intensive care unit (ICU) who received antibiotic treatment and for patients treated for ventilator associated pneumonia …
Increasing emergence of multidrug resistant (MDR) bacteria worldwide is now considered one of the most urgent threats to global health. The association between increase of antibiotics consumption and resistance emergence has been well documented for all patients admitted to the Intensive care unit (ICU) who received antibiotic treatment and for patients treated for ventilator associated pneumonia (VAP).
Reduction of use of antibiotics is a major point in the war against antimicrobial resistance. VAP is the first cause of healthcare-associated infections in ICU and more than half of antibiotics prescriptions in ICU are due to VAP.
Once the diagnosis of pneumonia under MV has been made, initiation of antibiotic treatment must be prompt but there is no clear consensus on its duration. In the case of a good clinical response to treatment, it has been shown in some situations that short course antibiotics can be effective without side effects and antimicrobial stewardship initiatives can be applied successfully and effectively to the management of Community Acquired Pneumonia (CAP).
The hypothesis is that an antimicrobial stewardship is possible in the treatment of VAP with no increase in the rate of all-cause mortality, treatment failure or occurrence of new episode of pneumonia.
The objective is to investigate whether an antimicrobial stewardship for VAP based on daily assessment of clinical cure and antimicrobial discontinuation, if it is obtained, would be non-inferior in terms of all-cause mortality, treatment failure or occurrence of new episode of pneumonia.
This study will be a prospective, national multicenter (31 centers), phase III, comparative randomized (1:1), single-blinded clinical trial comparing two management strategies of treatment of pneumonia on the basis of two parallel arms:
Experimental group: Antimicrobial stewardship based on daily clinical assessment of clinical cure.
Control group: standard management: duration of appropriate antibiotic therapy for confirmed VAP according to guidelines.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of microbiologically confirmed of first episode of VAP
* Initial appropriate antibiotic therapy (whether empirical or not)
* Written informed consent from the patient or a legal representative if appropriate. If absence of a legal representative the patient may be in…
Inclusion Criteria:
* Diagnosis of microbiologically confirmed of first episode of VAP
* Initial appropriate antibiotic therapy (whether empirical or not)
* Written informed consent from the patient or a legal representative if appropriate. If absence of a legal representative the patient may be included in emergency procedure
Definitive diagnosis of pneumonia (in agreement with international guidelines) is defined by association:
* Patient under MV\>48 hours at the time of the microbiological sampling
* New pulmonary infiltrate of which an infectious origin is strongly suspected
* Worsening oxygenation
* Have the following clinical criteria within the 24 hours prior to the first dose of antibiotic therapy
* Purulent tracheal secretions
* And at least 1 of the following : documented fever (body temperature \>38,3°C) or hypothermia (body temperature \<35°C) or white blood cell (WBC) count \>10,000 cells/mm3 or \<4,000 cells/mm3
* Microbiological criteria (positive quantitative culture of a lower respiratory tract (LRT): bronchoalveolar lavage fluid (BAL) (significant threshold ≥10\^4 colony-forming units/mL) or plugged telescopic catheter (PTC) (significant threshold ≥ 10\^3 colony-forming units/mL) or quantitative endotracheal aspirate (ETA) distal pulmonary secretion samples (significant threshold ≥10\^5 colony-forming units/mL)
Exclusion Criteria:
* Patient under selective decontamination of the digestive tract
* Duration of antibiotic therapy prior to inclusion \> 72h (for any reason) appropriate to the germs found in the bacterial documentation of the first episode of VAP
* Inclusion in another interventional study concerning antimicrobial strategies
* Moribund (IGS II\>80)
* Thoracic trauma with Abbreviated Injury Scale (AIS) thorax ≥ 3
* Severely immunocompromised patients (such as congenital immunodeficiency, neutropenia (\<1leucocyte/ml or \<0.5 neutrophil/ml) or acute hematologic malignancy or stem cell transplant, HIV infection with CD4 count below 200/mm3
* Patients undergoing immunosuppressive therapy and long term corticotherapy \> 0.5 mg/kg
* VAP due to: Pseudomonas aeruginosa, Carbapenem-resistant Acinetobacter spp, Carbapenem-resistant Enterobacteriaceae
* VAP occurring in the context of co-infection of COVID-19 or other viral pneumonia (confirmed by RT-PCR)
* Patients with empyema, necrotizing and abscessed pneumonia
* Patients requiring extracorporeal oxygen therapy (ECMO), either veno-venous or veno-arterial
* Pregnant women
* No health insurance coverage
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
